

GenCore version 5.1.3  
Copyright (c) 1993 - 2003 Comptech Ltd.

OM protein - protein search, using sw mode

Run on: January 16, 2003, 16:34:37, Search time: 62.6429 seconds

(without alignments)  
28 011 million result updates/sec

Title: US-09-856-070-19

Perfect score: 65

Sequence: 1 KEELMIRQYEE 13

Scoring table: HCONS62

Gapep 10.0 Gapwt 0.5

Searched: 608470 seqs; 133250620 residues

Total number of hits satisfying chosen parameters: 968470

Minimum DB seq length: 0

Maximum DB seq length: 20000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 5 summaries

Database: A\_Genesed\_101002.\*

1: /SIDS2/cregdata/genesed/geneseq/emb1/AA1989 DAT \*

2: /SIDS2/cregdata/genesed/geneseq/emb1/AA1989 DAT \*

3: /SIDS2/cregdata/genesed/geneseq/emb1/AA1989 DAT \*

4: /SIDS2/cregdata/genesed/geneseq/emb1/AA1989 DAT \*

5: /SIDS2/cregdata/genesed/geneseq/emb1/AA1984 DAT \*

6: /SIDS2/cregdata/genesed/geneseq/emb1/AA1985 DAT \*

7: /SIDS2/cregdata/genesed/geneseq/emb1/AA1996 DAT \*

8: /SIDS2/cregdata/genesed/geneseq/emb1/AA1988 DAT \*

9: /SIDS2/cregdata/genesed/geneseq/emb1/AA1989 DAT \*

10: /SIDS2/cregdata/genesed/geneseq/emb1/AA1989 DAT \*

11: /SIDS2/cregdata/genesed/geneseq/emb1/AA1990 DAT \*

12: /SIDS2/cregdata/genesed/geneseq/emb1/AA1991 DAT \*

13: /SIDS2/cregdata/genesed/geneseq/emb1/AA1992 DAT \*

14: /SIDS2/cregdata/genesed/geneseq/emb1/AA1993 DAT \*

15: /SIDS2/cregdata/genesed/geneseq/emb1/AA1994 DAT \*

16: /SIDS2/cregdata/genesed/geneseq/emb1/AA1995 DAT \*

17: /SIDS2/cregdata/genesed/geneseq/emb1/AA1996 DAT \*

18: /SIDS2/cregdata/genesed/geneseq/emb1/AA1997 DAT \*

19: /SIDS2/cregdata/genesed/geneseq/emb1/AA1998 DAT \*

20: /SIDS2/cregdata/genesed/geneseq/emb1/AA1999 DAT \*

21: /SIDS2/cregdata/genesed/geneseq/emb1/AA2000 DAT \*

22: /SIDS2/cregdata/genesed/geneseq/emb1/AA2001 DAT \*

23: /SIDS2/cregdata/genesed/geneseq/emb1/AA2002 DAT \*

24: /SIDS2/cregdata/genesed/geneseq/emb1/AA2003 DAT \*

25: /SIDS2/cregdata/genesed/geneseq/emb1/AA2004 DAT \*

26: /SIDS2/cregdata/genesed/geneseq/emb1/AA2005 DAT \*

27: /SIDS2/cregdata/genesed/geneseq/emb1/AA2006 DAT \*

28: /SIDS2/cregdata/genesed/geneseq/emb1/AA2007 DAT \*

29: /SIDS2/cregdata/genesed/geneseq/emb1/AA2008 DAT \*

30: /SIDS2/cregdata/genesed/geneseq/emb1/AA2009 DAT \*

31: /SIDS2/cregdata/genesed/geneseq/emb1/AA2010 DAT \*

32: /SIDS2/cregdata/genesed/geneseq/emb1/AA2011 DAT \*

33: /SIDS2/cregdata/genesed/geneseq/emb1/AA2012 DAT \*

34: /SIDS2/cregdata/genesed/geneseq/emb1/AA2013 DAT \*

35: /SIDS2/cregdata/genesed/geneseq/emb1/AA2014 DAT \*

36: /SIDS2/cregdata/genesed/geneseq/emb1/AA2015 DAT \*

37: /SIDS2/cregdata/genesed/geneseq/emb1/AA2016 DAT \*

38: /SIDS2/cregdata/genesed/geneseq/emb1/AA2017 DAT \*

39: /SIDS2/cregdata/genesed/geneseq/emb1/AA2018 DAT \*

40: /SIDS2/cregdata/genesed/geneseq/emb1/AA2019 DAT \*

41: /SIDS2/cregdata/genesed/geneseq/emb1/AA2020 DAT \*

42: /SIDS2/cregdata/genesed/geneseq/emb1/AA2021 DAT \*

43: /SIDS2/cregdata/genesed/geneseq/emb1/AA2022 DAT \*

44: /SIDS2/cregdata/genesed/geneseq/emb1/AA2023 DAT \*

45: /SIDS2/cregdata/genesed/geneseq/emb1/AA2024 DAT \*

46: /SIDS2/cregdata/genesed/geneseq/emb1/AA2025 DAT \*

47: /SIDS2/cregdata/genesed/geneseq/emb1/AA2026 DAT \*

48: /SIDS2/cregdata/genesed/geneseq/emb1/AA2027 DAT \*

49: /SIDS2/cregdata/genesed/geneseq/emb1/AA2028 DAT \*

50: /SIDS2/cregdata/genesed/geneseq/emb1/AA2029 DAT \*

51: /SIDS2/cregdata/genesed/geneseq/emb1/AA2030 DAT \*

52: /SIDS2/cregdata/genesed/geneseq/emb1/AA2031 DAT \*

53: /SIDS2/cregdata/genesed/geneseq/emb1/AA2032 DAT \*

54: /SIDS2/cregdata/genesed/geneseq/emb1/AA2033 DAT \*

55: /SIDS2/cregdata/genesed/geneseq/emb1/AA2034 DAT \*

56: /SIDS2/cregdata/genesed/geneseq/emb1/AA2035 DAT \*

57: /SIDS2/cregdata/genesed/geneseq/emb1/AA2036 DAT \*

58: /SIDS2/cregdata/genesed/geneseq/emb1/AA2037 DAT \*

59: /SIDS2/cregdata/genesed/geneseq/emb1/AA2038 DAT \*

60: /SIDS2/cregdata/genesed/geneseq/emb1/AA2039 DAT \*

Result No.	Score	Query	Match	Length	DB ID	Description	Location/Qualifiers
1	6.5	6.5	100.0	13	22	AAB82037	
2	6.5	100.0	34	22	AAB82020	Human heptreptin	
3	6.5	100.0	446	22	AGM73954	Human heptreptin	
4	6.5	100.0	586	20	AAY27443	Human heptreptin	
5	6.5	100.0	622	22	AMU30004	Novel heptreptin	
6	6.5	100.0	635	21	AAB53356	Human heptreptin	
7	6.0	92.3	12	22	AAB82038	Novel heptreptin	
8	5.7	87.7	52	22	AAU33040	Human heptreptin	
9	5.5	84.6	11	22	MBB82039	Autotaxin/peptidase	
10	4.1	63.1	27	20	AAY27444	Autotaxin/peptidase	
11	4.1	63.1	344	22	ABG20165	Novel human dipeptidyl peptidase	
12	4.0	61.5	46	22	AAM63126	Human brain exopeptidyl	
13	4.0	61.5	60.3	22	AHG15277	Novel human dipeptidyl	
14	4.0	61.5	59.5	22	ABG19347	Novel human dipeptidyl	
15	4.0	61.5	59.3	22	ABG93128	Human protease seq	
16	4.0	61.5	57	22	AAB33680	Peptide #7186 endo	
17	3.9	60.0	57	22	AAM60396	Human brain express	
18	3.9	60.0	57	22	AAM73032	Human bone marrow	
19	3.9	60.0	57	22	AAC7293	Peptide #47293 endo	
20	3.9	60.0	57	23	AHG42876	Human peptide enopeptidyl	
21	3.9	60.0	40.5	11	AMF01219	CDX, a MILA antibody	
22	3.9	60.0	40.5	12	AMR13752	GDP-Fuc beta-D-Gal	
23	3.9	60.0	40.5	13	AMR28810	HeLa cell lucosyl	
24	3.9	60.0	40.5	15	AAR45947	A 9'acyltransfer	
25	3.9	60.0	40.5	15	AAR45945	Human alpha(1,3)-f	
26	3.9	60.0	40.5	18	AAR13641	Human protease	
27	3.9	60.0	40.5	19	AAR11921	Human protease	
28	3.9	60.0	40.5	20	AFC16148	Novel human	
29	3.9	60.0	40.5	22	AAG74411	Human colon cancer	
30	3.9	60.0	40.5	22	AMR9338	A glycosyltransfer	
31	3.9	60.0	40.5	22	AHG19045	Novel human dipeptidyl	
32	3.9	60.0	40.5	22	AHG94332	Caenorhabditis cili	
33	3.9	60.0	264.5	22	AHG20077	Insulin/insulin-1	
34	3.8	58.5	64.1	21	AMG92816	Human bone marrow	
35	3.8	58.5	64.5	22	AMG66650	Human peptide enopeptidyl	
36	3.8	58.5	78.6	22	ABG58780	Ecdisophila melanostoma	
37	3.7	58.5	71.9	22	ABG47344	Festuca, F. abissi	
38	3.7	58.5	73.5	21	AAY73462	Kat 9a signalling	
39	3.7	58.5	1387	21	AAY95441	Caenorhabditis cili	
40	3.7	56.9	20.0	22	AAB82037	Insulin/insulin-1	
41	3.7	56.9	20.0	22	AMG2037	Human peptide enopeptidyl	
42	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
43	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
44	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
45	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
46	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
47	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
48	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
49	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
50	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
51	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
52	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
53	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
54	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
55	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
56	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
57	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
58	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
59	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
60	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
61	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
62	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
63	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
64	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
65	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
66	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
67	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
68	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
69	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
70	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
71	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
72	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
73	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
74	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
75	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
76	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
77	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
78	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
79	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
80	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
81	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
82	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
83	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
84	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
85	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
86	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
87	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
88	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
89	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
90	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
91	3.7	56.9	21.9	22	AMG2037	Human peptide enopeptidyl	
92							

xx Novel regulatory or unfolding peptides of ezrin that binds to  
pt hepreceptor, useful for inducing immune response for treating  
pt infections diseases and cancer -  
xx

ps claim 22: page 46; 42pp; English.

xx The hepreceptor is a novel active site in human ezrin. Ezrin regulates  
cc the structure of the cortical cytoskeleton to control cell surface  
cc topology. The present invention relates to peptides (see AAB82021 to  
cc AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see  
cc AAB82046). The hepreceptor binding peptides are useful for inducing  
cc immune response, and for treating infectious diseases, cancer and  
cc HIV-related dementia, the present peptide binds to domain A of the  
cc hepreceptor (AAB82049).

xx Sequence, 13 AA:

Query Match 100.0%; Score 65; DB 22; Length 13;  
Best Local Similarity 100.0%; Pred. No. 0.00055;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KEELMLRLQDYE 13

Db 1 KEELMLRLQDYE 13

KW Human; hepreceptor domain B; cytostatic; anti-HIV; antibiotic;  
cc toxicologic; immune response inducer; ezrin; infectious diseases; cancer;  
cc HIV-related dementia.

xx 13-JUN-2001 (first entry)

xx Human hepreceptor domain B.

DE Human hepreceptor domain B.

xx

KW Human; hepreceptor domain B; cytostatic; anti-HIV; antibiotic;  
cc toxicologic; immune response inducer; ezrin; infectious diseases; cancer;  
cc HIV-related dementia.

xx Homo sapiens.

OS Homo sapiens.

xx

PH KEELMLRLQDYE 13  
PT Modified-site 14  
ET /note- \*optionally phosphorylated\*

xx

DN GHB2354241-A.  
xx

PD 21-MAR-2001.

xx

FF 17-SEP-1999; 99GB-0021881.

xx

PR 17-SEP-1999; 99GB-0021881.

xx

PA (HOLM/1) HOLMS R D.

PT Holms RD.

xx

W17; 2901 293287731

xx Novel regulatory or unfolding peptides of ezrin that binds to  
pt hepreceptor, useful for inducing immune response for treating  
pt infections diseases and cancer -  
xx

ps claim 5: page 46; 42pp; English.

xx The present sequence is domain B of human hepreceptor of human ezrin. The  
cc hepreceptor is a novel active site in human ezrin. Ezrin regulates the  
cc structure of the cortical cytoskeleton to control cell surface  
cc topology. The present invention relates to peptides (see AAB82011 to  
cc AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see  
cc AAB82046). The hepreceptor binding peptides are useful for inducing

CC immune response, and for treating infectious diseases, cancer and  
CC HIV related dementia. The present sequence assembles into two  
CC anti-parallel helices with hepreceptor domain A (see AAB82019).

xx

Sequence 34 AA:

Query Match 100.0%; Score 65; DB 22; Length 34;  
Best Local Similarity 100.0%; Pred. No. 0.00155;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 KEELMLRLQDYE 13

Db 1 KEELMLRLQDYE 13

KW Human; colon cancer; colon cancer antigen; diagnosis; detection;

xx

RESULT 2  
AAB82020

xx AAH82020 standard; peptide; 34 AA.

xx

AC AAH82020;

xx

DT 03-SEP-2001 (first entry)

xx Human colon cancer antigen protein SEQ ID No:4718.

xx Human; colon cancer; colon cancer antigen; diagnosis; detection;

xx

RESULT 3  
AA673954

xx AA673954 standard; Protein; 436 AA.

xx

AC AA673954;

xx

DT 03-SEP-2001 (first entry)

xx Human colon cancer antigen protein SEQ ID No:4718.

xx Human; colon cancer; colon cancer antigen; diagnosis; detection;

xx

OS Homo sapiens.

xx

PN WO200122949-A2.

xx

PD 05-APR-2001.

xx

PF 28-SEP-2009; 2000WO-US26524.

xx

PR 29-SEP-1999; 99US-0157137.

xx

PR 03-NOV-1999; 99US-0163280.

xx

PA (HUMA-) HUMAN GENOME SCI INC.

xx

P1 Ruben SM, Barash SC, Hirse CE, Rosen CA;

xx

PR WPI; 2001 235357724.

xx

DR N-PSDB; AAII33385.

xx

PT Nucleic acids encoding 4277 human colon cancer-associated polypeptides, -

xx

PT useful for preventing, diagnosing and/or treating colorectal cancers -

xx

PS Claim 11; Page 6520 6521 9803pp; English.

xx

CC AAII32943-16 AAII37195 and AA673514 16 AA677788 represent human colon

CC cancer-associated nucleic acid molecules (N) and proteins (P), where

CC the proteins are collectively known as colon cancer antigens. The colon

CC cancer antigens have cytostatic activity and can be used in gene

CC therapy and vaccine production. N and P may be used in the prevention,

CC diagnosis and treatment of diseases associated with inappropriate P

CC expression. For example, N and P may be used to treat disorders

CC associated with decreased expression by rectifying mutations or deletions

CC in a patient's genome that affect the activity of P by expressing

CC inactive proteins or to supplement the patient's own production of P.

CC Additionally, N may be used to produce the colon cancer-associated PS,

CC by inserting the nucleic acids into a host cell and culturing the cell

CC to express the proteins. N and P can be used in the prevention, diagnosis

CC and treatment of colorectal carcinomas and cancers. AAII7196 to AAII7204

CC and AAII7789 represent sequences used in the exemplification of the

CC present invention.

CC N.B. Pages 66 to 682 and page 7053 of the sequence listing were

CC missing at time of publication, meaning no sequences are present for

CC SEQ ID No:1027 to 1052, 7921 and 7922.

xx Sequence 436 AA;



neural disorder; immune system disorder; muscular disorder; reproductive disorder; gastrointestinal disorder; renal disorder; infectious disease; cardiovascular disorder.

Homosapiens.

WO200055351-A1.  
21-SEP-2000.  
08 MAR-2030; 2006(WO) 0805883.  
12 MAR-1999; 99020124279.  
(HUMA-) HUMAN GENOME SCI INC.  
Rosen CA, Ruben SM.  
WPI: 2000-58754/55.  
N PSQLB; AAC98113.

colon cancer associated gene sequences, referred to as colon cancer antigens, can have cytostatic, cardiotrophic, muscular, neuroprotective, immunomodulatory, gynaecological, antiinfective and antibacterial activities, and can be used in gene therapy. The colon cancer antigen polynucleotides, proteins and antibodies of colon disorders, such as colon cancer, treatment and diagnosis of colon disorders, such as colon cancer, may be used in diagnostics and research, such as for chromosome identification, and as hybridisation probes. The proteins may also be used to prevent diseases such as neural disorders, immune system disorders, muscular disorders, reproductive disorders, gastrointestinal disorders, wounds, renal disorders, infectious diseases, and cardiovascular disorders. AAC98764 to AAC98772 and AAC98777 represent sequences used in the exemplification of the present invention.

colon cancer associated gene sequences, referred to as colon cancer antigens, given in AAC5334 to AAC54006. The human colon cancer antigens can have cytostatic, cardiotrophic, muscular, pulmonary, nephroprotective, antiinfective and antibacterial activities, and can be used in gene therapy. The colon cancer antigen polynucleotides, proteins and antibodies of colon disorders, such as colon cancer, treatment and diagnosis of colon disorders, such as colon cancer, may be used in diagnostics and research, such as for chromosome identification, and as hybridisation probes. The proteins may also be used to prevent diseases such as neural disorders, immune system disorders, muscular disorders, reproductive disorders, gastrointestinal disorders, wounds, renal disorders, infectious diseases, and cardiovascular disorders. AAC98764 to AAC98772 and AAC98777 represent sequences used in the exemplification of the present invention.

claim 11: page 1449, 1451; 2104pp; English.

AAC97691 to AAC98765 encode the human colon cancer associated proteins, called human colon cancer antigens, given in AAC5334 to AAC54006. The human colon cancer antigens can have cytostatic, cardiotrophic, muscular, pulmonary, nephroprotective, antiinfective and antibacterial activities, and can be used in gene therapy. The colon cancer antigen polynucleotides, proteins and antibodies of colon disorders, such as colon cancer, treatment and diagnosis of colon disorders, such as colon cancer, may be used in diagnostics and research, such as for chromosome identification, and as hybridisation probes. The proteins may also be used to prevent diseases such as neural disorders, immune system disorders, muscular disorders, reproductive disorders, gastrointestinal disorders, wounds, renal disorders, infectious diseases, and cardiovascular disorders. AAC98764 to AAC98772 and AAC98777 represent sequences used in the exemplification of the present invention.

Sequence	635 AA:	Score
Query Match	100.0%	Score
Best Local Similarity	100.0%	pred.
Matches 13; Conservative 0;	0;	Mis.
KEELMLRLQYEE 13		
KEELMLRLQYEE 405		
493		
SHLF 7		
IR624149		
AAIB82038 standard: peptide: 12 AA.		

AAH82038;  
13-JUN-2001 (first entry)  
Human heptereptor domain A binding peptide Rupe2132.  
Human; heptereptor; cytosatatic; anti-HIV; antibiotic;  
nootropic; immune response inducer; czrin; infectious  
HIV-related domain A.

*Homo sapiens*, Key modifications, *from* *2003* *figures*

/note- "optionally phosphorylated"	
FI	GB2154241-A.
XX	PN
XX	21-MAR-2001.
PD	
XX	
PF	17-SEP-1999; 99GB-0021881.
PF	17-SEP-1999; 99GB-0021881.
XX	
XX	(HYSLM-) HOLMS R. D.
PA	
XX	holms Rd;
PA	
XX	DR; 2001-293287/31.
XX	
PT	Novel regulatory or untolding peptides of egrin that
PT	receptor, useful for inducing immune response to
PT	infectious diseases and cancer.
XX	
PS	Claim 24; Page 36; 42pp; English.
XX	
CC	The hepreceptor is a novel active site in human ex-
CC	CC the structure of the cortical cytoskeleton to control
CC	CC topography. The present invention relates to peptide
CC	CC (AA82041) that bind to hepreceptor with greater of
CC	CC (AAB82045). The hepreceptor binding peptides are useful
CC	CC for immune response, and for treating infectious disease
CC	CC and Hiv related dementia. The present peptide binds to
CC	CC hepreceptor (AA82019).
XX	
SO	Sequence 12 AA;
	Query Match 92.3%; Score 60; DB 22; Les-
	Rest Local Similarity 100.0%; Pred. No. 0/0; 32;
	Matches 12; Conservative 0; Mismatches 0;
OY	2 FELMLRLQDYEE 13
	1 1 1 1 1 1 1 1 1
Db	1 FELMLRLQDYEE 12
	RESULT 8
	AAU33060
XX	ID AAU33060 standard; Protein: 52 AA.
XX	
AC	AAU33060;
XX	18-DEC-2001 (first entry)
DE	Novel human secreted protein #3551.
XX	
KW	Human; vaccination; gene therapy; nutritional sup-
KW	port; cell proliferation; haemoptysis; nerve tissue
KW	immune suppression; immune stimulation; anti-inflam-
XX	mos; Homo sapiens.
OS	
XX	WO200179449-A2.
XX	25-OCT-2001.
PD	
XX	16-APR-2001; 2001WO-US08656.
PF	
XX	18-APR-2001; 2000US-0552929.
PR	
PP	26-JAN-2001; 2001US-0770160.
XX	
PA	(HYSLM-) HYSEQ INC.
XX	
P1	Tang YT, Liu C, Drmanac RT;
XX	
PA	WPI; 2001-611725/70.
XX	
DE	

Nucleic acids encoding a range of human polypeptides, useful in genetic vaccination, testing and therapy.

Claim 20: Page 702, line 5-7. EP: Page 138.

The invention relates to novel human secreted polypeptides. The polypeptides and antibodies to the polypeptides are useful for determining the presence of or predisposition to a disease associated with altered levels of polypeptides. The polypeptides are also useful for identifying agents (agonists and antagonists) that bind to them. Cells expressing the proteins are useful for identifying a therapeutic agent for use in treatment of a pathology related to aberrant expression or physiological interactions of the polypeptide. Vectors encoding the nucleic acids encoding the polypeptides and cells genetically engineered to express them are also useful for producing the proteins. The proteins are useful in genetic vaccination, testing and therapy, and can be used as nutritional supplements. They may be used to increase stem cell proliferation; to regulate haemotopoeisis; and in bone, cartilage, tendon and/or nerve tissue growth or regeneration; immune suppression and/or stimulation; as anti inflammatory agents; and in treatment of leukaemias. AU2510-AU2504 represent the amino acid sequences of novel human secreted proteins of the invention.

XX the hepreceptor is a novel active site in human egrin. Egrin regulates the structure of the cortical cytoskeleton to control cell surface topology. The present invention relates to peptides (see AAB-251 to AAB-2641) that bind to hepreceptor with greater affinity than HAPI (see AAB-2646). The hepreceptor binding peptides are useful for inducing labour, resorption, and for treating infectious diseases, cancer and HIV-related diseases. The present peptides are hepreceptor binders (AAB-2019).

for use in treatment of a pathology related to aberrant expression or physiological interactions of the polypeptide. Vectors comprising the nucleic acids encoding the polypeptides and cells genetically engineered to express them are also useful for producing the proteins. The proteins are useful in genetic vaccination, testing and therapy, and can be used as nutritional supplements. They may be used to increase stem cell proliferation; to regulate haematopoiesis; and in bone, cartilage, tendon and/or nerve tissue growth or regeneration; immune suppression and/or stimulation; as anti-inflammatory agents; and in treatment of leukaemias. AAU29510-AAU3304 represent the amino acid sequences of novel human secreted proteins of the invention.	Query Match 94.6%; Score 55; DB 22; Length 11; Best Local Similarity 100.0%; Pred. No. 0.018; Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0
QY 3 EMLRLQDYE 13	QY 1111111111111111
Db 1 EMLRLQDYE 11	Db 1 EMLRLQDYE 11
RESULT 10	RESULT 10
AAU27444	AAU27444
TD AAU27444 standard, peptide, 27 AA.	TD AAU27444 standard, peptide, 27 AA.
XX	XX
AC AAU27444;	AC AAU27444;
XX	XX
LT 26-NOV-1993 (first entry)	LT 26-NOV-1993 (first entry)
XX	XX
DE Antennapedia internalization sequence in tandem with ezrin fragment.	DE Antennapedia internalization sequence in tandem with ezrin fragment.
XX	XX
KW Pharmaceutical, ezrin, mutant, tumor, antennapedia internalization;	KW Pharmaceutical, ezrin, mutant, tumor, antennapedia internalization;
KW metastasis; human.	KW metastasis; human.
XX	XX
OS Synthetic.	OS Synthetic.
XX	XX
FH Key-Modified-site 1	FH Key-Modified-site 1
FT /note- "biotinylated"	FT /note- "biotinylated"
FT Modified-site 22	FT Modified-site 22
FT /note "optionally phosphorylated"	FT /note "optionally phosphorylated"
XX	XX
FN W0947150 A2.	FN W0947150 A2.
XX	XX
PR 23-SEP-1999.	PR 23-SEP-1999.
PP 18-MAR-1997; 99WO-EP02054.	PP 18-MAR-1997; 99WO-EP02054.
XX	XX
PR 18-MAR-1998; 9905-0940725.	PR 18-MAR-1998; 9905-0940725.
XX	XX
PA (CUR1-) INST CURIE,	PA (CUR1-) INST CURIE,
PA (CNRS ) CNRS CENT NAT RCH SCI.	PA (CNRS ) CNRS CENT NAT RCH SCI.
XX	XX
PI Arpin M, Crepaldi T, Gautreau A, Louvard D;	PI Arpin M, Crepaldi T, Gautreau A, Louvard D;
XX	XX
DR 1999-561851/47.	DR 1999-561851/47.
XX	XX
FT New composition for prevention and treatment of tumors and metastasis	FT New composition for prevention and treatment of tumors and metastasis
PI	PI
XX	XX
PS Example 5; Page 14; 31pp; English.	PS Example 5; Page 14; 31pp; English.
XX	XX
CC The invention provides a pharmaceutical composition containing a protein, RNA or DNA mutation on tyrosine 353, or a functional fragment or derivative of the ezrin mutant. The new composition is useful for prevention and/or treatment of tumors, and especially metastasis. The present sequence represents an antennapedia internalization sequence in CC tandem with an ezrin fragment (residues 348-358). This is used in CC experiments of p85 interaction with phosphorylated e116 peptides.	CC The invention provides a pharmaceutical composition containing a protein, RNA or DNA mutation on tyrosine 353, or a functional fragment or derivative of the ezrin mutant. The new composition is useful for prevention and/or treatment of tumors, and especially metastasis. The present sequence represents an antennapedia internalization sequence in CC tandem with an ezrin fragment (residues 348-358). This is used in CC experiments of p85 interaction with phosphorylated e116 peptides.
WPI; 2001 293207/31.	WPI; 2001 293207/31.
Novel regulatory or inhibiting peptides of ezrin that binds to the receptor, useful for inducing immune response for treating infectious diseases and cancer.	Novel regulatory or inhibiting peptides of ezrin that binds to the receptor, useful for inducing immune response for treating infectious diseases and cancer.
Claim 36: Page 32, line 20-22, replace	Claim 36: Page 32, line 20-22, replace

Best Local Similarity 100.0%; Pred. No. 7.7%;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 EELMLRLQDYE 12  
Db 278 KELMLRLQDYE 288

RESULT 12  
ID ABB42735 standard; peptide: 46 AA.

XX AC AB42735;

XX DT 04-FEB-2002 (first entry)

XX Peptide #10241 encoded by human foetal liver single exon probe.

XX Human; foetal liver, gene expression, single exon nucleic acid probe.

XX KW foetal; liver, gene expression, single exon nucleic acid probe.

OS Homo sapiens.

PN WO200157277 A2.

XX PD 09-AUG-2001.

XX PF 30-JAN-2001; 2001WO-US0669.

XX PR 04-FEB-2002; 2000US-0180312.

XX PR 26-MAY-2002; 2000US-0207456.

XX PR 30-JUN-2002; 2000US-0608408.

XX PR 03-AT3-2003; 255-08-053466.

XX PR 21-SEP-2003; 2000US-024687.

XX PR 27-SEP-2003; 2000US-0236359.

XX PR 04-OCT-2003; 2000US-024263.

XX PA (MOLECULAR DYNAMICS INC.

XX PI Fenn SG, Hanzel DK, Chen W, Rank DR;

XX DR WO1 2001 0830841

XX PR 30-MAR-2001; 2001WO-US0669.

XX PR 41-MAR-2000; 2000US-054817.

XX PR 21-APR-2000; 2000US-0649167.

XX PA (HYSEQ INC.)

XX PI Dromatik RI, Lin C, Tang YI;

XX DR WO1 6 99362773.

XX DR N PSTD; AAS9352.

XX PS Claim 20: SEQ ID NO 59524; 103pp; English.

XX PR New isolated polynucleotide and encoded polypeptides, useful in  
PT diagnostics, forensics, gene mapping, identification of mutations  
PT responsible for genetic disorders or other traits and to assess  
PT biodiversity.

XX PR

XX The invention relates to isolated polynucleotide (I) and  
CC polyamide (II) sequences (I) is useful as hybridisation probes,  
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome  
CC and gene mapping, and in recombinant production of (II). The  
CC polyamides are also used in diagnostics, as expressed sequence tags  
CC to identify expressed genes. (I) is useful in gene therapy techniques  
CC to restore normal activity of (II) or to treat disease states involving  
CC quantitating a polypeptide in tissue, as molecular weight markers and as  
CC a food supplement. (II) and its binding partners are useful in medical  
CC imaging of sites expressing (II). (I) and (II) are useful for treating  
CC the polypeptide and polynucleotide sequences have applications in  
CC diagnostics, forensics, gene mapping, identification of mutations  
CC responsible for genetic disorders or other traits to assess biodiversity  
CC and to produce other types of data and products dependent on DNA and  
CC amino acid sequences. ABO00010-AB0377 represent novel human  
CC diagnostic amino acid sequences of the invention.

CC Note: the sequence data for this patent did not appear in the printed  
CC specification, but was obtained in electronic format directly from WIPO.  
XX Sequence 344 AA;

Query Match 63.1%; Score 41; L8 22; Length 344;  
Best Local Similarity 53.8%; Pred. No. 19;

Matches 7; Conservative 4; Mismatches 2; Indels 2; Gaps 0;

Db 31 KQNLJLLENEYEF 43

RESULT 13  
ID AAM63626

XX AC AAM63626;

XX DT 05-NOV-2001 (first entry)

XX Human brain expressed single exon probes, nucleic acid, protein, in SEQ ID No. 35731.  
 DE Human brain expressed exon gene expression analysis: probe;  
 XX microarray; Alzheimer's disease, multiple sclerosis, schizophrenia,  
 KW epilepsy; cancer.  
 XX Homo sapiens.  
 XX WO20015775-A2.  
 XX PD 09-AUG-2001.  
 XX DE 30-JAN-2001; 20031W01US00667.  
 XX PS 04-FEB-2000; 2003008-01807312.  
 XX PR 26-MAY-2000; 2003015-0307456.  
 XX PR 30-JUN-2000; 2003008-0608408.  
 XX PR 03-AUG-2000; 2003008-0612300.  
 XX PR 21-SEP-2000; 2003008-0614647.  
 XX PR 27-SEP-2000; 2003008-0203359.  
 XX PR 04-SEP-2000; 2003008-0203359.  
 XX PA (MOLE-) MOLECULAR DYNAMICS INC.  
 XX P1 Penn SG, Hanzel LR, Chen W, Rank DR;  
 XX DR WPI; 2001-481446/52.  
 XX Single exon nucleic acid probes for analyzing gene expression in human  
 PT brains.  
 XX Example 4: SEQ ID No. 35731; 650bp + Sequence List 14; English  
 CC The present invention provides a number of single exon nucleic acid  
 CC probes which are derived from genomic sequences expressed in the human  
 CC brain. They can be used to measure gene expression in brain cell samples,  
 CC which may enable the diagnosis and improved treatment of nervous system  
 CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,  
 CC epilepsy and cancers. The present sequence is a protein encoded by one of  
 CC the probes of the invention.  
 XX Sequence 46 AA:  
 Query Match 61.5%; Score 40; 39 22; Length 46;  
 Best Local Similarity 53.8%; Pred. No. 19;  
 Matches 7; Conservative 4; Mismatches 2; Indels 0; Gaps 0;  
 QY 1 KIEELMLPLQDYE 13  
 1: 1: 1: 1: 1: 1: 1:  
 Db 31 KQNLLELRNYYEE 43

RESULT 14  
 ABC16577  
 ID ABC16577 standard; Protein: 503 AA.  
 AC ABC16577.  
 XX DR 18-FEB-2002 (first entry)  
 XX DE Novel human diagnostic protein #19948.  
 XX Human; chromosome mapping; gene mapping; gene therapy; forensic;  
 KW food supplement; medical imaging; diagnostic; genetic disorder.  
 XX OS Homo sapiens.  
 XX PN WO200175067-A2.  
 XX PD 11-OCT-2001.  
 XX PR 30-MAR-2000; 20031W01-US008631.  
 PR 31-MAR-2000; 20031W01-US008631.

! XX 31-MAR-2002; 20031W01-US008631.  
 ! PR 23-AUG-2002; 20031W01-US049167.  
 ! XX  
 ! XX (HISEE ) HISEE INC.  
 ! FA  
 ! PI Ormanac RL, Liu C, Lang YT;  
 ! XX  
 ! XX WPI; 2001-639362/73.  
 ! DR N-PSDB; 6AS60764.  
 ! XX  
 ! PT New isolated polynucleotide and encoded polypeptides, useful in  
 ! PT diagnostics, forensics, gene mapping, identification of mutations  
 ! PT responsible for genetic disorders of other traits and to assess  
 ! PT biodiversity.  
 ! XX  
 ! XX Claim 20, SEQ ID No 46936, 163pp; English.  
 ! FS  
 ! XX The invention relates to isolated polynucleotide (I) and  
 ! CC polypeptide (II) sequences (I) is useful as hybridisation probes,  
 ! CC polymerase chain reaction (PCR) primers, oligonucleotides, and for chromosome  
 ! CC and gene mapping, and in recombinant production of (II). The  
 ! CC polynucleotides are also used in diagnostics as expressed sequence tags  
 ! CC for identifying expressed genes. (I) is useful in gene therapy techniques  
 ! CC to restore normal activity of (II) or to treat disease states involving  
 ! CC (II). (II) is useful for generating antibodies against it, detecting or  
 ! CC quantitating a polypeptide in tissue, as molecular weight markers and as  
 ! CC a food supplement. (II) and its binding partners are useful in medical  
 ! CC imaging of sites expressing (II). (I) and (II) are useful for treating  
 ! CC diseases involving aberrant protein expression or biological activity.  
 ! CC The polypeptide and polynucleotide sequences have applications in  
 ! CC diagnostics, forensics, gene mapping, identification of mutations  
 ! CC responsible for genetic disorders or other traits to assess biodiversity  
 ! CC and to produce other types of data and products dependent on DNA and  
 ! CC amino acid sequences ABG19947-ABG30377 represent novel human  
 ! CC diagnostic amino acid sequences of the invention.  
 ! CC Note: The sequence data for this patent did not appear in the printed  
 ! CC specification, but was obtained in electronic format directly from WIPO  
 ! CC at [http://wipo.int/patentpub/published\\_pct\\_sequences](http://wipo.int/patentpub/published_pct_sequences).  
 ! XX Sequence 503 AA:  
 ! QC Sequence Match 61.5%; Score 40; DB 22; Length 503;  
 ! QC Best Local Similarity 69.2%; Pred. No. 2-2c:02;  
 ! QC Matches 9, Conservative 1, Mismatches 3, Indels 6, Gaps 0;  
 ! QC QY 1 KIEELMLPLQDYE 13  
 ! QC 1:1:1:1:1:1:  
 ! DB 264 KIEELMLPLQDYE 275  
 ! XX RESULT 15  
 ! ABG19947  
 ! ID ABG19947 standard; Protein: 593 AA.  
 ! AC ABG19947;  
 ! XX DT 18 FEB 2002 (first entry)  
 ! XX DE Novel human diagnostic protein #19948.  
 ! XX Human; chromosome mapping; gene mapping; gene therapy; forensic;  
 ! KW food supplement; medical imaging; diagnostic; genetic disorder.  
 ! XX OS Homo sapiens.  
 ! XX PN WO200175067-A2.  
 ! XX PD 11-OCT-2001.  
 ! XX PR 30-MAR-2000; 20031W01-US008631.  
 ! PR 31-MAR-2000; 20031W01-US008631.

Fr 24 Aug 2000; 2000US 0649167.  
 XX  
 (HYSEQ INC.)

PA  
 (HYSEQ INC.)

XX  
 Inventor: RU, Liu C, Tang Y;

XX  
 WIPO; 2001-639362/73.

Fr  
 N-PSDB; AAS84134.

XX  
 Fr  
 New isolated polynucleotide and encoded polypeptides, useful in  
 diagnostics, forensics, gene mapping, identification of mutations  
 responsible for genetic disorders or other traits and to assess  
 biodiversity.

PS  
 Claim 20: SEQ ID No 5036: 103pp; English.

XX  
 The invention relates to isolated polynucleotide (I) and  
 polypeptide (II) sequences, (I) is useful as hybridisation probes,  
 polymerase chain reaction (PCR) primers, oligomers, and for chromosome  
 and gene mapping, and in recombinant production of (II). The  
 polynucleotides are also used in diagnostics as expressed sequence tags  
 for identifying expressed genes, (I) is useful in gene therapy techniques  
 to restore normal activity of (II) or to treat disease states involving  
 (II). (II) is useful for generating antibodies against it, detecting or  
 quantitating a polypeptide in tissue, as molecular weight markers and as  
 a food supplement. (II) and its binding partners are useful in medical  
 imaging of sites expressing (II). (I) and (II) are useful for treating  
 disorders involving aberrant protein expression or biological activity.  
 The polypeptide and polynucleotide sequences have applications in  
 diagnostics, forensics, gene mapping, identification of mutations  
 and to produce other types of data and products dependent on DNA and  
 amino acid sequences. And 00010-A0630377 represent novel human  
 diagnostic amino acid sequences of the invention.

Note: The sequence data for this patent did not appear in the printed  
 specification, but was obtained in electronic format directly from WIPO  
 at [http://wipo.int/pub/published\\_seq.html](http://wipo.int/pub/published_seq.html).

XX  
 Seq Sequence 593 AA;

Query Match 61.58; Score 49; DB 22; Length 593;  
 Best Local Similarity 69.28; Pred. No. 2,60+02;  
 Matches 9; Conservative 1; Mismatches 3; Indels 0; Gaps 0;  
 OY 1 KEELMEROOTEE 13  
 1b 359 KEELMEROOTEE 371

Search completed: January 16, 2003, 16:49:14  
 Job time: 62.8429 secs